Short answer: CagriSema is Novo Nordisk's investigational combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) - two molecules, two complementary pathways. The Phase 3 REDEFINE program reported mean weight reductions in the region of roughly 20-23% at 68 weeks. It is one of the clearest signals that amylin is the next obesity-research mechanism. Investigational, not approved, supplied here research use only.
For a decade, obesity research has been a GLP-1 story. CagriSema is one of the strongest signs that the next chapter adds a second hormone - amylin - alongside it. This profile explains what cagrilintide is, why it is paired with semaglutide, what the REDEFINE trials reported, and where the combination sits in the pipeline.
Plain-English summary. CagriSema and cagrilintide are research-stage molecules, not medicines you can buy or use. Everything below describes published preclinical and clinical-trial findings for laboratory and educational context. New-U supplies research-use-only material and does not provide dosing, medical, or human-use guidance.
Cagrilintide is a long-acting analogue of amylin - the hormone co-secreted with insulin that researchers associate with satiety, meal termination, and appetite regulation. It is the amylin half of CagriSema and is also studied on its own.
Semaglutide acts on the GLP-1 pathway; cagrilintide acts on the amylin pathway. Pairing them is a bet that two complementary satiety mechanisms produce more weight reduction together than either alone - and it leverages Novo Nordisk's existing semaglutide infrastructure.
In the Phase 3 REDEFINE program, CagriSema reported mean weight reductions in the region of roughly 20-23% at 68 weeks, placing it among the most effective obesity combinations studied to date.
CagriSema (GLP-1 + amylin) and tirzepatide (GLP-1 + GIP) are frequently compared, including in head-to-head clinical research, because they represent two different two-pathway strategies for weight reduction.
CagriSema sits alongside a wave of amylin-containing candidates - the single-molecule amycretin and the amylin-only petrelintide - that together make amylin one of the most closely watched mechanisms in metabolic research.
CagriSema has completed Phase 3 work with regulatory filings anticipated, putting it among the nearest-term next-generation obesity combinations. Timelines remain subject to regulatory review.
What is CagriSema?
Novo Nordisk's investigational combination of cagrilintide (amylin analogue) + semaglutide (GLP-1) - two molecules, two complementary pathways. Investigational, not approved; research use only.
What is cagrilintide?
A long-acting amylin analogue - the amylin half of CagriSema, also studied on its own.
How much weight loss did it show?
The Phase 3 REDEFINE program reported roughly 20-23% mean weight reduction at 68 weeks.
Is CagriSema FDA approved?
No - it is investigational with filings anticipated. Material supplied as cagrilintide or CagriSema is research use only, not for human consumption.
Research use disclaimer. This content is intended for scientific discussion and educational purposes only. No medical advice, treatment recommendations, dosing guidance, or human-use instructions are provided.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog